References
PubMed- Murray et al. Lancet 1997; 349: 1269–1276.
- NICE. Technical Appraisal 90. 2005.
- Patrignani P, Filabozzi P, Patrono C. J Clin Invest 1982, 69: 1366-1372.
- Patrono et al. Chest 2001, 119: 39-63.
- Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-1184.
- Pfisterer M, Burkart F, Jockers G, et al. Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. Lancet 1989; 2: 1-7.
- National Stroke Association supports FDA guidelines for secondary stroke prevention [press release]. Englewood, Colo: National Stroke Association; October 23, 1998.
- National Stroke Association supports newly-released American College of Chest Physicians guidelines [press release]. Englewood, Colo: National Stroke Association; December 2, 1998.
- National Stroke Association. The Stroke/Brain Attack Reporter's Handbook. 3rd ed. Englewood, Colo: Postgraduate Institute for Medicine; 1999.
- Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-1489.
- Rosamond et al. American Heart Association. Circulation 2008; 117: e25–e146
- Rothwell et al. Lancet 2007; 370: 1432-1442
- Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association Prevention Conference IV: stroke-risk factors. Stroke 1997; 28: 1507-1517.
- Sacco et al. Arch Neurol 2005; 62 (3): 403-408.
- Sacco RL, Diener HC, Yusuf S et al. N Engl J Med 2008; 359
- The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-1349.
- Salzman EW. Cyclic AMP and platelet function. N Engl J Med 1972; 286: 358-363.
- Sarti et al. Stroke 2000; 31: 1588–1601.
- Serebruany V. Am J Hematology 2003, 72: 280-281.
- Sorensen PS, Pedersen H, Marquardsen J, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible ischemic attacks: a Danish cooperative study. Stroke 1983; 14: 15-22.
- Souness JE, Diocee BK, Martin W, et al. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases: use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells. Biochem J 1990; 266: 127-132.
- Svensson J, Samuelsson K. Thromb Res 1983, 31: 499-505.
- Swedish Cooperative Study Group. High-dose acetylsalicylic acid after cerebral infarction: a Swedish Cooperative Study. Stroke 1987; 18: 325-334.
- Theis JG et al. Br J Clin Pharmacol 1999;48:750-755
- Thijs et al. Eur Heart J 2008; Mar 17
- Thom et al. American Heart Association. Circulation 2006; 113: e85–e151
- Tijssen JGP. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. Neurology 1998; 51 (Suppl 3): S15-S16.
- UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054.
- Van der Maelen C. Neurology 2002, 58: A312.
- Venturini CM, Weston LK, Kaplan JE. Platelet cGMP, but not cAMP, inhibits thrombin-induced platelet adhesion to pulmonary vascular endothelium. Am J Physiol 1992; 63: H606-H612.
- Verro et al. Stroke 2008; 39: 1358–1363
- Warach, Kidwell. Neurology 2004; 62: 359–360.
- Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308: 800-805.
- Weyrich et al. Circulation 2005; 111: 633–642.
- WHO neurological disorders report 2007: 151–163.
- Wolf PA, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack. Stroke 1999; 30: 1991-1994.
- Zahavi M, Zahavi J, Kakkar VV. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation. Thromb Haemost 1984; 52: 205-209
